View ValuationGenix Pharmaceuticals 将来の成長Future 基準チェック /06現在、 Genix Pharmaceuticalsの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Personal Products 収益成長32.8%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesBoard Change • May 22Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Chairman of the Board & President Mahmoud Aziz was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • May 01Genix Pharmaceuticals Corporation, Annual General Meeting, Jul 08, 2026Genix Pharmaceuticals Corporation, Annual General Meeting, Jul 08, 2026.Board Change • Mar 03Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Chairman of the Board & President Mahmoud Aziz was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Jan 13Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Chairman of the Board & President Mahmoud Aziz was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Nov 21Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Chairman of the Board & President Mahmoud Aziz was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Nov 05Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Chairman of the Board & President Mahmoud Aziz was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Oct 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Chairman of the Board & President Mahmoud Aziz was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Sep 23Third quarter 2025 earnings released: CA$0.001 loss per share (vs CA$0.001 loss in 3Q 2024)Third quarter 2025 results: CA$0.001 loss per share (in line with 3Q 2024). Net loss: CA$83.5k (loss widened 1.6% from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.Board Change • Sep 10Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Chairman of the Board & President Mahmoud Aziz was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Aug 20Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Chairman of the Board & President Mahmoud Aziz was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Aug 13Genix Pharmaceuticals Corporation announced that it expects to receive CAD 0.1 million in fundingGenix Pharmaceuticals Corporation announced that it has entered into a non brokered private placement to issue 2,000,000 units at an issue price of CAD 0.05 for the proceeds of CAD 100,000 on August 11, 2025. Each Unit will be comprised of one common share and one warrant. Each whole warrant will entitle the holder thereof to purchase one common share for a period of 2 years at a price of CAD 0.10. All securities issued and sold under the Offering will be subject to a hold period expiring four months and one day from their date of issuance. The transaction is subject to regulatory and stock exchange approval. Certain directors and officers of the company are expected to participate in the Offering.Reported Earnings • Jun 20First half 2025 earnings released: CA$0.003 loss per share (vs CA$0.002 loss in 1H 2024)First half 2025 results: CA$0.003 loss per share (further deteriorated from CA$0.002 loss in 1H 2024). Net loss: CA$159.2k (loss widened 9.8% from 1H 2024). Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 33% per year, which means it is performing significantly worse than earnings.Board Change • Jun 17Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Chairman of the Board & President Mahmoud Aziz was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • May 15Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Chairman of the Board & President Mahmoud Aziz was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Apr 14Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Chairman of the Board & President Mahmoud Aziz was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Apr 01Genix Pharmaceuticals Corporation, Annual General Meeting, May 29, 2025Genix Pharmaceuticals Corporation, Annual General Meeting, May 29, 2025.Reported Earnings • Feb 28Full year 2024 earnings released: CA$0.001 loss per share (vs CA$0.074 loss in FY 2023)Full year 2024 results: CA$0.001 loss per share (improved from CA$0.074 loss in FY 2023). Revenue: CA$4.1k (down 67% from FY 2023). Net loss: CA$73.2k (loss narrowed 98% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 31% per year but the company’s share price has fallen by 38% per year, which means it is performing significantly worse than earnings.Board Change • Feb 28Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Chairman of the Board & President Mahmoud Aziz was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Sep 22Third quarter 2024 earnings released: CA$0.001 loss per share (vs CA$0.003 loss in 3Q 2023)Third quarter 2024 results: CA$0.001 loss per share (improved from CA$0.003 loss in 3Q 2023). Net loss: CA$82.2k (loss narrowed 50% from 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 46% per year whereas the company’s share price has fallen by 44% per year.Reported Earnings • Jun 28Second quarter 2024 earnings released: CA$0.001 loss per share (vs CA$0.004 loss in 2Q 2023)Second quarter 2024 results: CA$0.001 loss per share (improved from CA$0.004 loss in 2Q 2023). Net loss: CA$85.9k (loss narrowed 63% from 2Q 2023). Over the last 3 years on average, earnings per share has fallen by 41% per year but the company’s share price has only fallen by 33% per year, which means it has not declined as severely as earnings.Board Change • Jun 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Chairman of the Board & President Mahmoud Aziz was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.New Risk • Feb 29New major risk - Negative shareholders equityThe company has negative equity. Total equity: -CA$1.1m This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$221k free cash flow). Shares are highly illiquid. Negative equity (-CA$1.1m). Earnings have declined by 47% per year over the past 5 years. Revenue is less than US$1m (CA$12k revenue, or US$9.1k). Market cap is less than US$10m (CA$2.37m market cap, or US$1.75m).お知らせ • Mar 20Genix Pharmaceuticals Corporation, Annual General Meeting, May 19, 2021Genix Pharmaceuticals Corporation, Annual General Meeting, May 19, 2021. Location: Suite 1100-1111 Melville Street Vancouver British Columbia CanadaIs New 90 Day High Low • Jan 27New 90-day high: CA$0.25The company is up 35% from its price of CA$0.18 on 23 October 2020. The Canadian market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Personal Products industry, which is up 4.0% over the same period.分析記事 • Jan 17Did Genix Pharmaceuticals Corporation (CVE:GENX) Insiders Buy Up More Shares?We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On...Is New 90 Day High Low • Jan 05New 90-day high: CA$0.22The company is up 29% from its price of CA$0.17 on 06 October 2020. The Canadian market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Personal Products industry, which is down 6.0% over the same period.お知らせ • Dec 17Genix Pharmaceuticals Corporation Announces Executive ChangesGenix Pharmaceuticals Corporation announced the appointment of Danny Lee as Chief Financial Officer. Mr. Lee will replace Jamie Lewin as CFO who will remain a director of the Company and will assist in the transition of this role to Mr. Lee. Mr. Lee is a Chartered Professional Accountant with more than 20 years of experience working with public companies in mineral exploration, software, technology and distribution. Mr. Lee's experience includes financial reporting for both Canadian and US listed companies with international operations, corporate finance, strategic planning, tax planning, corporate governance, equity financings and due diligence for acquisitions.Reported Earnings • Sep 30Third quarter earnings releasedOver the last 12 months the company has reported total losses of CA$182.3k, with losses widening by 41% from the prior year.お知らせ • Sep 23Genix Pharmaceuticals Corporation Elects Darryl Yea to the Board of DirectorsGenix Pharmaceuticals Corporation announced that at its annual general meeting held on September 18, 2020, the shareholders elected Darryl Yea to the board of directors. Mr. Yea is currently president of Investco Capital Management Inc. He was formerly chairman, president and chief executive officer of Datawest Solutions Inc. Mr. Yea was a former member of the board of governors of the Vancouver Stock Exchange.お知らせ • Aug 07Genix Pharmaceuticals Corporation announced that it has received CAD 1.026734 million in fundingOn August 6, 2020, Genix Pharmaceuticals Corporation (TSXV:GENX) closed the transaction. The company issued 2,571,667 units for proceeds of CAD 385,750 in its second and final tranche. The company received gross proceeds of CAD 1,026,734 in the transaction. The warrant issued will have the expiry date of August 8, 2022, subject to acceleration. In connection with the second and final tranche, the company paid cash commissions of CAD 6,825 and issued 45,500 finders warrants pursuant to and in accordance with applicable securities laws and TSX Venture Exchange policies. The finder’s warrants have the same terms as the Warrants. All securities issued in conjunction with the final tranche closing have a hold period expiring four months and one day following closing. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Genix Pharmaceuticals は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測TSXV:GENX - アナリストの将来予測と過去の財務データ ( )CAD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数1/31/2026N/A000N/A10/31/2025N/A000N/A7/31/20250000N/A4/30/20250000N/A1/31/20250000N/A10/31/20240000N/A7/31/20240-400N/A4/30/20240-400N/A1/31/20240-400N/A10/31/20230-400N/A7/31/20230-100N/A4/30/20230-100N/A1/31/20230-100N/A10/31/2022N/A-100N/A7/31/2022N/A-100N/A4/30/2022N/A-100N/A1/31/2022N/A-200N/A10/31/2021N/A-200N/A7/31/2021N/A-2-10N/A4/30/2021N/A-1-10N/A1/31/2021N/A-100N/A10/31/2020N/A-100N/A7/31/20200000N/A4/30/20200000N/A1/31/20200000N/A10/31/201900N/A0N/A7/31/201900N/A0N/A4/30/201900N/A0N/A1/31/201900N/A0N/A10/31/201800N/A0N/A7/31/201800N/A0N/A4/30/201800N/A0N/A1/31/201800N/A0N/A10/31/201700N/A0N/A7/31/201710N/A0N/A4/30/201710N/A0N/A1/31/201710N/A0N/A10/31/201610N/A0N/A7/31/201610N/A0N/A4/30/201610N/A0N/A1/31/201610N/A0N/A10/31/20151-1N/A0N/A7/31/201510N/A0N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: GENXの予測収益成長が 貯蓄率 ( 3% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: GENXの収益がCanadian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: GENXの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: GENXの収益がCanadian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: GENXの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: GENXの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YHousehold 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/23 06:10終値2026/05/22 00:00収益2026/01/31年間収益2025/10/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Genix Pharmaceuticals Corporation 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Board Change • May 22Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Chairman of the Board & President Mahmoud Aziz was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • May 01Genix Pharmaceuticals Corporation, Annual General Meeting, Jul 08, 2026Genix Pharmaceuticals Corporation, Annual General Meeting, Jul 08, 2026.
Board Change • Mar 03Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Chairman of the Board & President Mahmoud Aziz was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Jan 13Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Chairman of the Board & President Mahmoud Aziz was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Nov 21Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Chairman of the Board & President Mahmoud Aziz was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Nov 05Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Chairman of the Board & President Mahmoud Aziz was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Oct 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Chairman of the Board & President Mahmoud Aziz was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Sep 23Third quarter 2025 earnings released: CA$0.001 loss per share (vs CA$0.001 loss in 3Q 2024)Third quarter 2025 results: CA$0.001 loss per share (in line with 3Q 2024). Net loss: CA$83.5k (loss widened 1.6% from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.
Board Change • Sep 10Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Chairman of the Board & President Mahmoud Aziz was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Aug 20Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Chairman of the Board & President Mahmoud Aziz was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Aug 13Genix Pharmaceuticals Corporation announced that it expects to receive CAD 0.1 million in fundingGenix Pharmaceuticals Corporation announced that it has entered into a non brokered private placement to issue 2,000,000 units at an issue price of CAD 0.05 for the proceeds of CAD 100,000 on August 11, 2025. Each Unit will be comprised of one common share and one warrant. Each whole warrant will entitle the holder thereof to purchase one common share for a period of 2 years at a price of CAD 0.10. All securities issued and sold under the Offering will be subject to a hold period expiring four months and one day from their date of issuance. The transaction is subject to regulatory and stock exchange approval. Certain directors and officers of the company are expected to participate in the Offering.
Reported Earnings • Jun 20First half 2025 earnings released: CA$0.003 loss per share (vs CA$0.002 loss in 1H 2024)First half 2025 results: CA$0.003 loss per share (further deteriorated from CA$0.002 loss in 1H 2024). Net loss: CA$159.2k (loss widened 9.8% from 1H 2024). Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 33% per year, which means it is performing significantly worse than earnings.
Board Change • Jun 17Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Chairman of the Board & President Mahmoud Aziz was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • May 15Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Chairman of the Board & President Mahmoud Aziz was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Apr 14Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Chairman of the Board & President Mahmoud Aziz was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Apr 01Genix Pharmaceuticals Corporation, Annual General Meeting, May 29, 2025Genix Pharmaceuticals Corporation, Annual General Meeting, May 29, 2025.
Reported Earnings • Feb 28Full year 2024 earnings released: CA$0.001 loss per share (vs CA$0.074 loss in FY 2023)Full year 2024 results: CA$0.001 loss per share (improved from CA$0.074 loss in FY 2023). Revenue: CA$4.1k (down 67% from FY 2023). Net loss: CA$73.2k (loss narrowed 98% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 31% per year but the company’s share price has fallen by 38% per year, which means it is performing significantly worse than earnings.
Board Change • Feb 28Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Chairman of the Board & President Mahmoud Aziz was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Sep 22Third quarter 2024 earnings released: CA$0.001 loss per share (vs CA$0.003 loss in 3Q 2023)Third quarter 2024 results: CA$0.001 loss per share (improved from CA$0.003 loss in 3Q 2023). Net loss: CA$82.2k (loss narrowed 50% from 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 46% per year whereas the company’s share price has fallen by 44% per year.
Reported Earnings • Jun 28Second quarter 2024 earnings released: CA$0.001 loss per share (vs CA$0.004 loss in 2Q 2023)Second quarter 2024 results: CA$0.001 loss per share (improved from CA$0.004 loss in 2Q 2023). Net loss: CA$85.9k (loss narrowed 63% from 2Q 2023). Over the last 3 years on average, earnings per share has fallen by 41% per year but the company’s share price has only fallen by 33% per year, which means it has not declined as severely as earnings.
Board Change • Jun 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Chairman of the Board & President Mahmoud Aziz was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
New Risk • Feb 29New major risk - Negative shareholders equityThe company has negative equity. Total equity: -CA$1.1m This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$221k free cash flow). Shares are highly illiquid. Negative equity (-CA$1.1m). Earnings have declined by 47% per year over the past 5 years. Revenue is less than US$1m (CA$12k revenue, or US$9.1k). Market cap is less than US$10m (CA$2.37m market cap, or US$1.75m).
お知らせ • Mar 20Genix Pharmaceuticals Corporation, Annual General Meeting, May 19, 2021Genix Pharmaceuticals Corporation, Annual General Meeting, May 19, 2021. Location: Suite 1100-1111 Melville Street Vancouver British Columbia Canada
Is New 90 Day High Low • Jan 27New 90-day high: CA$0.25The company is up 35% from its price of CA$0.18 on 23 October 2020. The Canadian market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Personal Products industry, which is up 4.0% over the same period.
分析記事 • Jan 17Did Genix Pharmaceuticals Corporation (CVE:GENX) Insiders Buy Up More Shares?We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On...
Is New 90 Day High Low • Jan 05New 90-day high: CA$0.22The company is up 29% from its price of CA$0.17 on 06 October 2020. The Canadian market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Personal Products industry, which is down 6.0% over the same period.
お知らせ • Dec 17Genix Pharmaceuticals Corporation Announces Executive ChangesGenix Pharmaceuticals Corporation announced the appointment of Danny Lee as Chief Financial Officer. Mr. Lee will replace Jamie Lewin as CFO who will remain a director of the Company and will assist in the transition of this role to Mr. Lee. Mr. Lee is a Chartered Professional Accountant with more than 20 years of experience working with public companies in mineral exploration, software, technology and distribution. Mr. Lee's experience includes financial reporting for both Canadian and US listed companies with international operations, corporate finance, strategic planning, tax planning, corporate governance, equity financings and due diligence for acquisitions.
Reported Earnings • Sep 30Third quarter earnings releasedOver the last 12 months the company has reported total losses of CA$182.3k, with losses widening by 41% from the prior year.
お知らせ • Sep 23Genix Pharmaceuticals Corporation Elects Darryl Yea to the Board of DirectorsGenix Pharmaceuticals Corporation announced that at its annual general meeting held on September 18, 2020, the shareholders elected Darryl Yea to the board of directors. Mr. Yea is currently president of Investco Capital Management Inc. He was formerly chairman, president and chief executive officer of Datawest Solutions Inc. Mr. Yea was a former member of the board of governors of the Vancouver Stock Exchange.
お知らせ • Aug 07Genix Pharmaceuticals Corporation announced that it has received CAD 1.026734 million in fundingOn August 6, 2020, Genix Pharmaceuticals Corporation (TSXV:GENX) closed the transaction. The company issued 2,571,667 units for proceeds of CAD 385,750 in its second and final tranche. The company received gross proceeds of CAD 1,026,734 in the transaction. The warrant issued will have the expiry date of August 8, 2022, subject to acceleration. In connection with the second and final tranche, the company paid cash commissions of CAD 6,825 and issued 45,500 finders warrants pursuant to and in accordance with applicable securities laws and TSX Venture Exchange policies. The finder’s warrants have the same terms as the Warrants. All securities issued in conjunction with the final tranche closing have a hold period expiring four months and one day following closing.